
Pfizer plans to close its neuroscience discovery and early development programs, the latest large drug maker to turn its corporate back on developing drugs for central nervous system disorders. As a result, about 300 jobs are being eliminated from three different Pfizer locations — Cambridge and Andover, Mass., and Groton, Conn.
The programs were primarily focused on Alzheimer’s and Parkinson’s disease, according to a Pfizer spokesman. As of Oct. 31, a Pfizer web page that is no longer visible listed nine neuroscience projects under way — six that were in Phase 1, two more in Phase 2, and another in Phase 3.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.